Systemic therapy and novel agents for metastatic castration resistant prostate cancer

Update on Cancer Therapeutics

Volumn 3, Issue 3, 2009, Pages 133-145

  Fleming, Mark T ^a   Sonpavde, Guru ^a   Kondagunta, G Varuni ^a   Galsky, Matthew D ^a   Hutson, Thomas E ^a   Sternberg, Cora N ^b  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Prostate

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; ATRASENTAN; BEVACIZUMAB; CETUXIMAB; DASATINIB; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ENZASTAURIN; EPOTHILONE DERIVATIVE; ESTRAMUSTINE PHOSPHATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYDROCORTISONE; ISOSORBIDE; KETOCONAZOLE; MITOXANTRONE; MONOCLONAL ANTIBODY; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; PREDNISOLONE; PREDNISONE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; UNINDEXED DRUG; VACCINE; VINBLASTINE; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; CANCER PAIN; CANCER PATIENT; CANCER RESEARCH; CASTRATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESEARCH; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SYSTEMIC THERAPY;

EID: 63749125511     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2008.10.002     Document Type: Review

References (122)

1. Jemal A., Siegel R., and Ward E. Cancer Statistics, 2008. CA Cancer J Clin 58 2 (2008) 71-96
2. Singer E.A., Golijanin D.J., Miyamoto H., and Messing E.M. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 9 2 (2008) 211-228
3. Tannock I.F., Osoba D., and Stockler M.R. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 6 (1996) 1756-1764
4. Kantoff P.W., Halabi S., and Conaway M. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 Study. J Clin Oncol 17 8 (1999) 2506-2513
5. Berry W., Dakhil S., and Modiano M. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168 6 (2002) 2439-2443
6. Bubley G.J., carducci M., and Dahut W. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 11 (1999) 3461-3467
7. Picus J., and Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26 5 Suppl. 17 (1999) 14-18
8. Berry W., Dakhil S., Gregurich M.A., and Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28 4 Suppl. 15 (2001) 8-15
9. Beer T.M., Pierce W.C., Lowe B.A., and Henner W.D. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12 9 (2001) 1273-1279
10. Savarese D.M., Halabi S., and Hars V. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780: Cancer and Leukemia Group B. J Clin Oncol 19 9 (2001) 2509-2516
11. Petrylak D.P., Macarthur R., and O'Connor J. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 26 5 Suppl. 17 (1999) 28-33
12. Sinibaldi V.J., Carducci M.A., and Moore-Cooper S. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94 5 (2002) 1457-1465
13. Tannock I.F., de Wit R., and Berry W.R. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 15 (2004) 1502-1512
14. Berthold D.R., Pond G.R., and Soban F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival of the TAX 327 study. J Clin Oncol 26 2 (2008) 242-245
15. Armstrong A.J., Garrett-Mayer E., and Yang Y.C. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13 21 (2007) 6396-6403
16. Armstrong A.J., Garrett-Mayer E., and Yang Y.C. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25 25 (2007) 3965-3970
17. Petrylak D.P., Tangen C.M., and Hussain M.H. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 15 (2004) 1513-1520
18. Petrylak D.P., Ankerst D.P., and Joang C.S. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98 8 (2006) 516-521
19. Oudard S., Banu E., and Beuzeboc P. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23 15 (2005) 3343-3351
20. Scher H.I., Halabi S., and Tannock I. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 7 (2008) 1148-1159
21. Dahut W.L., Scripture C., and Posadas E. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14 1 (2008) 209-214
22. Therasse P., Arbuck S.G., and Eisenhauer E.A. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
23. Moreno J., DeBono J.S., and Shaffer D. Multi-center study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC). ASCO Annual Meeting Proceedings Part I. vol. 25, No. 18S (June 20 Supplement). J Clin Oncol (2007) 5016
24. Fowler Jr. J.E., and Whitmore Jr. W.F. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126 3 (1981) 372-375
25. Taylor C.D., Elson P., and Trump D.L. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11 11 (1993) 2167-2172
26. Hussain M., Wolf M., and Marshall E. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 12 9 (1994) 1868-1875
27. Dawson N.A. Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials. J Clin Oncol 16 10 (1998) 3398-3405
28. Fowler Jr. J.E., Pandey P., Seaver L.E., and Feliz T.P. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 154 2 Pt 1 (1995) 448-453
29. Scher H.I., Liebertz C., and Kelly W.K. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15 8 (1997) 2928-2938
30. Joyce R., Fenton M.A., and Rode P. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 159 1 (1998) 149-153
31. Dawson N.A., Conaway M., and Halabi S. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: Cancer and Leukemia Group B Study 9181. Cancer 88 4 (2000) 825-834
32. Small E.J., and Srinivas S. The antiandrogen withdrawal syndrome: experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76 8 (1995) 1428-1434
33. Schellhammer P.F., Venner P., and Haas G.P. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 157 5 (1997) 1731-1735
34. Hara T., Miyazaki J., and Araki H. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63 1 (2003) 149-153
35. Small E.J., Baron A.D., Fippin L., and Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 157 4 (1997) 1204-1207
36. Small E.J., Halabi S., and Dawson N.A. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22 6 (2004) 1025-1033
37. Harris K.A., Weinberg V., and Bok R.A. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 168 2 (2002) 542-545
38. Shahidi M., Norman A.R., and Gadd J. Prospective review of diethylstilbestrol in advanced prostate cancer no longer responding to androgen suppression. Proc Am Soc Clin Oncol (2001) [Abstract 2455]
39. Rosenbaum E., Wygoda M., and Gips M. Diethystilbestrol is an active agent in prostate cancer patients after failure to complete androgen blockade. Proc Am Soc Clin Oncol (2000) [Abstract 1372]
40. Bland L.B., Garzotto M., and DeLoughery T.G. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer 103 4 (2005) 717-723
41. Beekman K.W., Fleming M.T., and Scher H.I. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer 4 2 (2005) 86-90
42. Berry W.R., Hathorn J.W., and Dakhil S.R. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer 3 2 (2004) 104-111
43. Hudes G., Einhorn L., and Ross E. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17 10 (1999) 3160-3166
44. Hudes G., Ross E., and Roth B. Improved survival for patients with hormone-refractory prostate cancer receiving estramustine-based antimicrotubule therapy: final report of a Hoosier Oncology Group and Fox Chase Network phase III trial comparing vinblastine and vinblastine plus oral estramustine phosphate. Proc Am Soc Clin Oncol (2002) [Abstract 704]
45. Lubiniecki G.M., Berlin J.A., Weinstein R.B., and Vaughn D.J. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis. Cancer 101 12 (2004) 2755-2759
46. Fizazi K., Le Maitre A., and Hudes G. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 8 11 (2007) 994-1000
47. Yagoda A., Watson R.C., and Natale R.B. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 44 5 (1979) 1553-1562
48. Miglietta L., Cannobbio L., and Boccardo F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res 15 6B (1995) 2825-2828
49. Steineck G., Reuter V., and Kelly W.K. Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol 41 7-8 (2002) 668-674
50. Kelly W.K., Curley T., and Slovin S. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19 1 (2001) 44-53
51. Oh W.K., Halabi S., and Kelly W.K. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 98 12 (2003) 2592-2598
52. Danila D.C., Rathkopf D., and Fleisher M. Preliminary phase II results of abiraterone acetate in patients with castration-resistant metastatic prostate cancer after failure of docetaxel-based chemotherapy. Genitourinary Cancer Symposium. San Francisco, CA (2008) [Abstract 3]
53. Reid A.H., Attard G., and Molife R. Selective CYP17 inhibition with abiraterone acetate (AA) results in a high response rate (RR) in castration-resistant prostate cancer (CRPC) confirming the continued importance of targeting androgen receptor (AR) signaling. Genitourinary Cancer Symposium. San Francisco, CA (2008) [Abstract 50]
54. Ioffe M.L., White E., and Nelson D.A. Epothilone induced cytotoxicity is dependent on p53 status in prostate cells. Prostate 61 (2004) 243-247
55. Galsky M.D., Small E.J., and Oh W.K. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23 7 (2005) 1439-1446
56. Hussain M., Tangen C.M., and Lara Jr. P.N. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 23 34 (2005) 8724-8729
57. Rosenberg J.E., Weinberg V.K., and Kelly W.K. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110 3 (2007) 556-563
58. Chi K.N., Beardsley E.K., and Venner P.M. A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel. J Clin Oncol 26 May (Suppl.) (2008) [abstr 5166]
59. Sternberg C.N., Whelan P., and Hetherington J. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68 1 (2005) 2-9 [Epub Feb 28, 2005]
60. Sartor A.O., Petrylak D.P., and Witjes J.A. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial. J Clin Oncol 26 May (Suppl.) (2008) [abstr 5003]
61. Nelson J.B., Nabulsi A.A., and Vogelzang N.J. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 169 3 (2003) 1143-1149
62. Carducci M.A., Saad F., and Abrahamsson P.A. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110 9 (2007) 1959-1966
63. Carducci M.A., and Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 12 20 Pt 2 (2006) 6296s-6300s
64. Picus J., Halabi S., and Rini B. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006. Proc Am Soc Clin Oncol 22 (2003) 393 (Abstr 1578)
65. Dupont J., Rothenberg M.L., and Spriggs D.R. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 23 (2005) 3029
66. Chi K.N., Ellard S.L., and Hotte S.J. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 19 4 (2008) 746-751
67. Steinbild S., Mross K., and Frost A. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 97 11 (2007) 1480-1485
68. Periman P., Sonpavde G., and Bernold D.M. Sunitinib malate for metastatic castration resistant prostate cancer following docetaxel-based chemotherapy. J Clin Oncol 26 May (Suppl.) (2008) [Abstr 5157]
69. George D.J., Liu G., and Wilding G. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC)-preliminary results. J Clin Oncol 26 May (Suppl.) (2008) [Abstr 5131]
70. Figg W.D., Dahut W., and Duray P. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7 (2001) 1888-1893
71. Dahut W.L., Gulley J.L., and Arlen P.M. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2532-2539
72. Ning Y.M., Gulley J., and Arlen P. Phase II trial of thalidomide, bevacizumab, and docetaxel in patients with metastatic castration-refractory prostate cancer (CRPC). Proc Am Soc Clin Oncol (2008) [Abstract 5000]
73. Garcia J.A., Cooney M.M., and Elson P. Clinical activity of ketoconazole and lenalidomide in castrated progressive prostate carcinoma (CPPCA): preliminary results of a phase II trial. Genitourinary Cancer Symposium. San Francisco, CA (2008) [Abstract 27]
74. Moss R.A., Mohile S.G., and Shelton G. A phase I open-label study using lenalidomide and docetaxel in androgen independent prostate cancer (AIPC). Prostate Cancer Symposium. Orlando, FL (2007) [Abstract 89]
75. Getzenberg R.H., Light B.W., and Lapco P.E. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50 (1997) 999-1006
76. Beer T.M., Eilers K.M., and Garzotto M. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21 1 (2003) 123-128
77. Beer T.M., Ryan C.W., and Venner P.M. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 25 6 (2007) 669-674
78. Novacea Press Release November 2007.
79. McDonnell T.J., Troncoso P., and Brisbay S.M. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52 (1992) 6940-6944
80. Tolcher A.W., Chi K., and Kuhn J. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11 10 (2005) 3854-3861
81. Sternberg C.N., Dumez H., and Van Poppel H. Multicenter randomized EORTC trial 30021 of docetaxel + oblimersen and docetaxel in patients (pts) with hormone refractory prostate cancer (HRPC). Prostate Cancer Symposium. Orlando, FL (2007) [Abstract 144]
82. Loberg R.D., McGregor N., and Ying C. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia 9 12 (2007) 1030-1037
83. Liu H., Moy P., and Kim S. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57 (1997) 3629-3634
84. Bander N.H., Milowsky M.I., and Nanus D.M. Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer. J Clin Oncol 23 21 (2005) 4591-4601
85. Milowsky M.I., Nanus D.M., and Kostakoglu L. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22 13 (2004) 2522-2531
86. Lara Jr. P.N., Chee K.G., and Longmate J. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100 10 (2004) 2125-2131
87. de Bono J., Bellmunt J., and Attard G. An open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 25 (2007) 257-262
88. Canil C.M., Moore M.J., and Winquist E. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23 3 (2005) 455-460
89. Small E.J., Fontana J., and Tannir N. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 100 4 (2007) 765-769
90. Gravis G., Bladou F., and Salem N. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol May 7 (2008) [Epub ahead of print]
91. Gross M., Higano C., and Pantuck A. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 7 (2007) 142
92. Whang Y.E., Moore C.N., and Armstrong A.J. A phase II trial of lapatinib in hormone refractory prostate cancer. J Clin Oncol 26 May (Suppl.) (2008) [Abstr 16037]
93. Park S.I., Zhang J., and Phillips K.A. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68 9 (2008) 3323-3333
94. Yu E.Y., Wilding G., and Posadas E. Dasatinib in patients with metastatic hormone-refractory (castration-resistant) progressive prostate cancer: a phase II study. Proc Am Soc Clin Oncol (2008) [Abstract 5156]
95. Grossmann M.E., Huang H., and Tindall D.J. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93 (2001) 1687-1697
96. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23 (2005) 8253-8261
97. Small E.J., Schellhammer P.F., and Higano C.S. Placebo-Controlled Phase III Trial of Immunotherapy with APC8015for Patients with Hormone Refractory Prostate Cancer. J Clin Oncol 24 19 (2006) 3089-3094
98. Higano C.S., Burch P.A., and Small E.J. Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): final progression and survival data from a second phase 3 trial. Program and abstracts of the 13th European Cancer Conference. Paris, France October 30-November 3 (2005) [Abstract PS1]
99. Simons J., Higano C., and Smith D. Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer. Proc Am Soc Clin Oncol (2005) [Abstract 2517]
100. Gulley N., Todd N., and Dahut W. A phase II study of a PSA-TRICOM vaccine, and the role of GM-CSF, in patients (pts) with metastatic androgen insensitive prostate cancer (AIPC). Paper Presented At: Prostate Cancer Symposium. Orlando, FL, February 17-19 (2005) [Abstract 287]
101. Small E.J., Tchekmedyian N.S., and Rini B.I. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13 6 (2007) 1810-1815
102. Rini B.I., Fong L., and Weinberg V. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol 175 6 (2006) 2087-2091
103. Chi K.N., Eisenhauer E., and Fazli L. A Phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2 > 29>-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97 (2005) 1287-1296
104. Chi K.N., Siu L.L., and Hirte H. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14 3 (2008) 833-839
105. Chi K.N., Hotte S.J., and Yu E. A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC). ASCO Annual Meeting Proceedings Part I. vol. 25, No. 18S (June 20 Supplement). J Clin Oncol (2007) 5069
106. Saad F., Hotte S.J., and North S. A phase II randomized study evaluating custirsen (OGX-011) in patients with hormone refractory prostate cancer (HRPC) who relapsed on or within 6 months of first-line docetaxel therapy. Proc Am Soc Clin Oncol (2008) [Abstract 5002]
107. Carducci M.A., Musib L., and Kies M.S. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24 25 (2006) 4092-4099
108. Wu L., Birle D.C., and Tannock I.F. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65 7 (2005) 2825-2831
109. Morgan T.M., Pitte T.E., and Gross T.S. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 68 8 (2008) 861-871
110. Solit D.B., Zheng F.F., and Drobnjak M. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8 5 (2002) 986-993
111. Sonpavde G., Aparicio A., and Guttierez I. Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. Clin Genitourin Cancer 5 7 (2007) 457-459
112. Wedel S.A., Sparatore A., and Del Soldato P. New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma. J Cell Mol Med (2008) [Feb 8. Epub ahead of print]
113. Saad F., Gleason D.M., and Murray R. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 19 (2002) 1458-1468
114. Saad F., Gleason D.M., and Murray R. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 11 (2004) 879-882
115. Small E.J., Smith M.R., and Seaman J.J. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21 23 (2003) 4277-4284 [Epub Oct 27, 2003]
116. McClung M.R., Lewiecki C.M., and Cohen S.B. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 8 (2006) 821-831
117. Le Gall C., Bellahcene A., and Bonnelye E. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 67 20 (2007) 9894-9902
118. Sartor O., Reid R.H., and Hoskin P.J. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63 5 (2004) 940-945
119. Tu S.M., Millikan R.E., and Mengistu B. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357 9253 (2001) 336-341 [Erratum in: Lancet 2001; 357 (9263) 1210]
120. 153Sm repetitively administered for castrate metastatic prostate cancer (CMPC). J Clin Oncol 26 May (Suppl.) (2008) [Abstr 5001]
121. Tomlins S.A., Rhodes D.R., and Perner S. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
122. Nelson W.G., De Marzo A.M., and Isaacs W.B. Mechanisms of disease: prostate cancer. N Engl J Med 349 (2003) 366-381